Park J W, Vermeltfoort M, Braun P, May E, Merz M
Herzzentrum Duisburg Kaiser-Wilhelm-Krankenhaus, Germany.
Atherosclerosis. 1995 May;115(1):1-8. doi: 10.1016/0021-9150(95)91034-o.
This report concerns a heart transplant patient with hypercholesterolemia who showed rapid development of a severe transplant coronary artery disease. The patient received 10 mg pravastatine per day. Quantitative coronary angiography analyses of 4 serial angiograms clearly demonstrated that in the first 2.5 years following surgery, there was a rapid simultaneous progression in both the transplant coronary disease, involving the entire coronary system, and the development of segmental stenotic lesions. During one year of weekly heparin-mediated extracorporeal LDL-cholesterol precipitation (HELP) therapy in addition to diet and pravastatine therapy, the serum low density lipoprotein (LDL), lipoprotein (a) (Lp(a)), and fibrinogen levels could be reduced from 185 +/- 45 mg/dl, 138 mg/dl and 248 mg/dl, respectively, to interval values of 136 +/- 17 mg/dl, 48 +/- 15 mg/dl, and 185 +/- 44 mg/dl, respectively [interval value = (the concentration after HELP + the concentration before the next HELP treatment):2]. This therapy halted further progression of coronary diameter throughout the whole coronary system and brought about marked regression of segmental obstructive lesions.
本报告涉及一名患有高胆固醇血症的心脏移植患者,该患者出现了严重的移植冠状动脉疾病的快速发展。患者每天接受10毫克普伐他汀治疗。对4次连续血管造影进行的定量冠状动脉造影分析清楚地表明,在手术后的最初2.5年中,涉及整个冠状动脉系统的移植冠状动脉疾病以及节段性狭窄病变均迅速同时进展。在除饮食和普伐他汀治疗外每周进行一年的肝素介导的体外低密度脂蛋白胆固醇沉淀(HELP)治疗期间,血清低密度脂蛋白(LDL)、脂蛋白(a)[Lp(a)]和纤维蛋白原水平可分别从185±45毫克/分升、138毫克/分升和248毫克/分升降至区间值136±17毫克/分升、48±15毫克/分升和185±44毫克/分升[区间值=(HELP治疗后浓度+下次HELP治疗前浓度):2]。该治疗阻止了整个冠状动脉系统冠状动脉直径的进一步进展,并使节段性阻塞性病变显著消退。